Clinical Studies Experience
Because clinical studies are conducted under widely varying conditions, adverse reaction rates observed in the clinical studies of a drug cannot be directly compared to rates in the clinical studies of another drug and may not reflect the rates observed in practice. During clinical trials, 1401 subjects were exposed to EPIDUO gel. A total of 1036 subjects with acne vulgaris, 12 years and older, were treated once daily for 12 weeks to 12 months. Related adverse events reported within 12 weeks of treatment and in at least 1% of subjects treated with EPIDUO gel and those reported in subjects treated with the vehicle gel are presented in Table 1:
Table 1 : Drug Related
Adverse Events Reported in Clinical Trials by At Least 1% of Patients Treated
For 12 Weeks
|System Organ Class/ Preferred Term||EPIDUO gel
N = 564
N = 489
|Subjects with AE (s)||14%||4%|
|Contact dermatitis||3%||< 1%|
|Application site burning||2%||< 1%|
|Application site irritation||1%||< 1%|
Table 2 : Incidence of Local
Cutaneous Irritation in Controlled Clinical Trials (N = 553) Treatment Emergent
Signs and Symptoms
|Maximum Severity During Treatment||End of Treatment Severity (12 Weeks)|
Analysis over the 12-week period showed that local tolerability scores for erythema, scaling, dryness, and stinging/burning peaked at Week 1 of therapy and decreased thereafter.
During a pediatric clinical trial, 285 children with acne vulgaris, 9 to 11 years of age were treated with EPIDUO gel or with the vehicle gel once daily for 12 weeks. Overall, the safety profile of EPIDUO gel in these subjects is comparable to the safety profile observed in older subjects 12 years of age and above, both in the nature and frequency of the observed events.
Analysis of local tolerability evaluations shows similar incidence of treatment emergent signs and symptoms as in subjects 12 years of age and above, with local tolerability signs and symptoms peaking during the first week and decreasing over time.
The following adverse reactions have been identified during postapproval use of EPIDUO Gel: eyelid edema, sunburn, blister, pain of skin, pruritus, swelling face, conjunctivitis, skin discoloration, rash, eczema, throat tightness and allergic contact dermatitis. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.
Read the Epiduo Gel (adapalene and benzoyl peroxide gel) Side Effects Center for a complete guide to possible side effects
Concomitant topical acne therapy should be used with caution because a possible cumulative irritancy effect may occur, especially with the use of peeling, desquamating, or abrasive agents. No formal drug-drug interaction studies were conducted with EPIDUO gel.This monograph has been modified to include the generic and brand name in many instances.
Last reviewed on RxList: 2/26/2013
Additional Epiduo Gel Information
Epiduo Gel - User Reviews
Epiduo Gel User Reviews
Now you can gain knowledge and insight about a drug treatment with Patient Discussions.
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Find out what women really need.